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for the meta-analysis; they globally include 624 patients (163 ENE+ and 461 ENE-) with a median follow-up of 58 months. ENE was associated with a higher risk of both mortality (RR= 2.51; 95% CI: 1.66-3.79, p<0.0001, I 2 =0%) and recurrence of disease (RR=2.07, 95%CI: 1.38-3.10, p<0.0001, I 2 =0%). These findings recommend the consideration of ENE from the gross sampling to the histopathological evaluation, in perspectives to be validated and included in the oncologic staging.
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INTRODUCTION
Invasive breast cancer is the most common malignancy in women, representing 23% of all cancers in woman globally and 27% in affluent countries. It is more than twice as common as cancer at any other site [1] . The most common site of metastasis of breast cancer is represented by the lymph nodes of axilla, and the sentinel lymph node (SLN) is the first station of nodal metastasis [1] [2] [3] .
Axillary SLN biopsy was introduced in the management of patients affected by T1
and T2 breast cancer and has become the standard care for these patients, being an accurate method in predicting other axillary lymph nodes status [2] [3] . The probability of non-SLN metastases in patients with SLN free of metastases is less than 5%. For this reason, such patients can safely avoid axillary lymph node dissection and the associated morbidity [2] [3] [4] [5] [6] . Patients with positive SLN were traditionally treated with axillary lymph node dissection [5] [6] . However, about 40-60% of these patients have no other metastatic axillary lymph nodes, suggesting that even this group is heterogeneous.
Several factors have been studied as potential predictors of the status of axillary lymph nodes in patients with positive SLN, and some of them have not demonstrated a prognostic value. For example, the presence of isolated tumor cells in the SLN does not adversely impact disease free-and overall-survival, and, according to the Tumor, Nodes, Metastasis (TNM) staging system, isolated tumor cells are designated and treated as pN0(i+) [7] . At the same time, extranodal extension (ENE) has recently emerged as an important prognostic factor in several types of malignancies [8] [9] [10] [11] . It is the extension of neoplastic cells through the nodal capsule into the peri-nodal M A N U S C R I P T
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adipose tissue (Figure 1) . In positive SLN, ENE has been indicated as a possible predictor of non-SLN tumor burden in breast cancer, but it is yet unclear if ENE in SLN has a significant prognostic impact [12] .
In order to study in depth the prognostic role of ENE in positive SLN of breast cancer patients, we conducted a systematic review and meta-analysis of all the studies that have investigated the most important prognostic indicators, including overall survival (OS), disease-free survival (DFS) and cancer-specific survival, in patients with
MATERIALS AND METHODS
This systematic review adhered to the MOOSE guidelines [13] and PRISMA statement [14] , following a predetermined but unpublished protocol.
Inclusion and exclusion criteria
Studies were considered eligible for inclusion if they satisfy the following criteria 
Study selection
Following the searches as outlined above, after removal of duplicates, two reviewers 
Data extraction
Two authors were involved in the data extraction from a predetermined Excel database. Particularly, one author (A.N.) extracted data from the included articles and a second independent author (C.L.) validated the data. For each article, we extracted information about authors, year of publication, country, exclusion criteria, tumor size and grading, age, ENE definition, and duration of mean follow-up. In case of missing data, authors were contacted at least 4 times in one month by e-mail.
Outcomes
The main outcomes were number of deaths independent from all the causes (all-cause mortality), number of deaths due to cancer (cancer-specific mortality), and number of recurrences (disease free survival) during follow-up period by ENE status.
Assessment of study quality
The Newcastle-Ottawa Scale (NOS) [15] was used to evaluate study quality. The NOS provides an assessment of the methodological quality of non-randomized trials and its content validity and reliability have already been established [13] . Included studies are judged on 8 items across three key areas: selection of the participants, comparability of the participants, and outcomes. One author (C.L.) completed the NOS and each study receives an overall score for methodological quality of up to 9
points.
Data synthesis and statistical analysis
All analyses were conducted using Comprehensive Meta-Analysis (CMA) 3.
In our primary analyses, pooled risk ratios (RRs) and 95% CIs of all-cause mortality and recurrences of disease between ENE+ vs. ENE-were calculated using DerSimonian-Laird random-effects models [16] . Since data about hazard ratios (HRs) adjusted for the maximum number of covariates were available only for two studies, we summarized these findings descriptively.
Heterogeneity across studies was assessed by the I 2 metric and chi square statistics [17] . Since no outcome from the meta-analysis was heterogeneous, (i.e. I 2 >50%
and/or a p-value <0.05 [15] ), no meta-regression analysis was performed.
Finally, we investigated publication bias for our primary meta-analysis with a visual inspection of funnel plots and with the Begg-Mazumdar Kendall's tau [18] and Egger bias test [19] .
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RESULTS
Search Results
Altogether, 172 non-duplicated articles were identified through the literature search.
After excluding 160 articles based on title/abstract review, 12 articles were retrieved for full text review and, following the application of the inclusion criteria (exclusion of 7 studies: doubled cohort = 1 study, no data on SLN = 3 studies, reviews = 2 studies, no control group = 1 study), 5 unique articles resulted as eligible for this meta-analysis [20] [21] [22] [23] [24] (Supplementary Figure 1) .
Study and Patient Characteristics
The studies were conducted in Europe (2 studies) [21, 24] , Asia (2 studies) [22, 23] and
North America (1 study) [20] . Altogether, 624 patients (163 ENE+ and 461 ENE-)
were followed-up for a median of 58 months (range: 20-73). The median NOS score was 6 points (range: 5-9) (Supplementary Tables 1-2 ).
All studies (except one) defined ENE using a classical definition, i.e. as the presence of full-thickness lymph node capsular invasion or with the extension of tumor cells into peri-nodal adipose tissue. Only one study [23] reported salient demographic data by ENE status limiting the applicability to these findings to other studies.
Risk Ratios on Overall survival and Disease-Free Survival
Pooling data from 4 studies reporting data on overall survival [20, 21, 23, 24] , 22.5%
with ENE+ for sentinel lymph node were dead vs. 9.6% with ENE-, leading to a significant increased risk of mortality (RR= 2.51; 95% CI: 1.66-3.79, p<0.0001, I 2 =0%) (Table 1; Figure 2A) . ENE+ was further associated to a significant higher M A N U S C R I P T No studies reported data on cancer-specific mortality.
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Descriptive findings
Two studies [20, 23] [25, 26] . These results were further corroborated with a meta-analysis by van la Parra et al. [12] . In this meta-analysis 8 factors including ENE in the SLN were identified as predictive of non-SLN tumor burden. With the size of SLN metastasis (>2 mm vs. ≤2 mm), ENE emerged as one of the most clinically relevant indexes to predict further non-SLN metastasis [12] . Despite a well-defined role of ENE in the SLN metastasis in the prediction of non-SLN involvement, its role as a prognostic factor in terms of overall mortality has not been established until now. Our findings show that the presence of ENE in SLN is strongly associated with a poor prognosis in terms of overall survival and disease free survival. Although there were not a sufficient number of studies reporting the HR, adjusted for potential confounders, to perform a meta-analysis, the present findings based on RR appear sufficiently robust to generate the hypothesis of a significant prognostic role of ENE in SLN positive breast cancer.
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There are some important implications that can be derived from this study. The first regards the need of a standard definition of ENE, since this parameter, should be considered by future staging systems and also be reported in the final pathology report. Four out of 5 studies assessed ENE classically, i.e. as the extension of metastatic cells through the nodal capsule into the perinodal adipose tissue [20, 21, 23, 24] . The study by Fujii et al. [22] considered ENE as the extra-capsular growth of tumor cells, the invasion of perinodal fat or the extranodal location of tumor cells, extending in this way the classic definition. Using this definition, also free tumor deposits in the adipose tissue surrounding the SLN could be included in our meta-analysis, introducing a possible bias. However, this study represents a minor proportion (7.4%) of the total number of ENE+ patients to significantly affect our findings, and as discussed before no heterogeneity was present.
This point further reiterates the importance of adopting a standard definition of ENE.
We suggest define as true ENE the one that is demonstrated histologically and characterized by a structural rupture of the lymph node capsule by the metastasis.
Neoplastic emboli as well as free tumor cell deposits in adipose tissue and metastasis in the marginal sinus should not be considered as true ENE. Notably, the presence of tumor cells in the adipose tissue is recognized as associated to a poor prognosis in colorectal cancer. In this type of cancer, this parameter has been recognized by the TNM staging system designing for it a specific subcategory of N group, named N1c [7, 9] . Furthermore, ENE has also been taken into account in the last staging systems of squamous cell carcinoma of the vulva, playing an important, adverse prognostic role [11] . In the 5 th edition of the American Joint Committee on Cancer (AJCC)
Cancer Staging Manual, ENE was considered also for breast cancer, in a specific subcategory, named pN1biii, but this was removed from the 6th edition of the same M A N U S C R I P T
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13 staging system [27, 28] . It is possible that some evidences against its usefulness in the staging system and also problems in the standardization of ENE definition, with a difficult inter-observer agreement, affected the consideration of its prognostic importance. However, on the basis of the present results, we suggest to reconsider the possible prognostic role of ENE, also in perspectives to be validated by future clinical trials.
Recently, the Z0011 trial demonstrated no difference in loco-regional recurrence and overall survival in breast cancer patients with a positive SLN randomized to axillary lymph node dissection or no further surgery, changing the surgical management of T1
and T2 breast cancer patients with metastatic involvement of the axilla limited to the SLN [29] . However, it is important recognizing patients who meet the Z0011 strict criteria of inclusion but at the same time have a certain high-risk characteristics, as for example the presence of ENE. The incidence of ENE in SLN ranges from 24% to 40% [20, 26, 30] . Due to its high incidence, due to its association with non-SLN metastasis, as even highlighted by Cserni and Stitzenberg et al. in a multivariate analysis [25, 26] , and by van la Parra et al. in a meta-analsysis [12] , and also due to the results of this meta-analysis, it seems advisable to offer completion of the axillary lymph node dissection, rather than not.
When considering the therapeutic in other cancer types (e.g. pancreatic ductal adenocarcinoma), ENE+ patients seem to benefit from adjuvant chemo-radiation, but not from chemotherapy alone [8, 31] . This aspect should be further addressed by future studies, and could address peculiar therapeutic approaches if confirmed also for breast cancers as well. Noticeably, even after the Z0011 trial, some radiation oncologists still recommend additional radiation fields in selected cases such as ENE+ in SLN [20, 32] .
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Whilst the results of this meta-analysis are clear and reliable, we have also to consider some limitations of our paper. The first is the small number of studies; however, the significant number of patients presented in these studies (mean number: 125 patients/study) as well as their high NOS quality index and the absence of a high heterogeneity of the results ensure a certain grade of reliability. Furthermore, data about other co-morbidities (like cardio-vascular diseases) were not reported by the primary studies, but it's known that they play an important role in the prognosis also of patients with cancer. Moreover, it lacks a comprehensive landscape of the clinical data of the patients, since only one study [23] reported this kind of information (tumor size, nodal status, tumor grading) by ENE status, limiting general considerations about these topics. Therefore, future research should try and disentangle the role of co-morbidities on the observed results and should report more complete clinical data.
Another limitation of this meta-analysis derived from the lack of data from multivariate analyses: only two studies [20, 23] presented data from multivariate models, both significant, but not comparable with a meta-analysis (odds ratios in a study [20] vs hazard ratios in the other [23] ). Future studies should consider also this important point, reporting data on ENE from multivariate analysis.
Concluding, the present data indicate that ENE in SLN positive breast cancer seems to be strongly associated with a poorer prognosis in breast cancer. Its consideration becomes thus essential from the gross sampling to the histopathological evaluation and the oncologic staging. In spite of the recently developed techniques (e.g. DNA sequencing) which allow integrating the pathological report with a complete molecular characterization of the tumor in the so called "next-generation histopathological analysis" [33, 34] , all the prognostic roles of the pure morphologic features and of the histologic aspects, including ENE, should be clarified. 
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